Until now, travelers could not be protected against meniningitis B. Vaccines (Menactra, Menomune) have been available only against serogroups C, Y, and W135. Until recently, there were no serogroup B meningococcal vaccines licensed for use in the United States.
On October 29, 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal vaccine (Trumenba®). FDA approved this vaccine for use in people 10-25 years of age as a 3-dose series. On January 23, 2015, FDA licensed a second serogroup B meningococcal vaccine (Bexsero®). FDA approved this vaccine for use in people 10-25 years of age as a 2-dose series. While there is no routine recommendation for serogroup B meningococcal vaccines at this time, physicians can use these vaccines for people 10-25 years of age consistent with the labeled indication.
Share this post